Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) Director Charles Duncan bought 5,803 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, November 5th. The stock was purchased at an average cost of $3.80 per share, with a total value of $22,051.40. Following the completion of the acquisition, the director directly owned 108,701 shares in the company, valued at $413,063.80. This represents a 5.64% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Charles Cliff Duncan also recently made the following trade(s):
- On Wednesday, November 4th, Charles Duncan bought 3,447 shares of Vanda Pharmaceuticals stock. The shares were purchased at an average price of $3.82 per share, for a total transaction of $13,167.54.
- On Tuesday, November 3rd, Charles Duncan purchased 750 shares of Vanda Pharmaceuticals stock. The shares were purchased at an average cost of $3.80 per share, for a total transaction of $2,850.00.
Vanda Pharmaceuticals Price Performance
Shares of NASDAQ:VNDA opened at $3.59 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.54 and a quick ratio of 1.53. Vanda Pharmaceuticals Inc. has a 1-year low of $3.57 and a 1-year high of $9.94. The company has a market capitalization of $217.09 million, a P/E ratio of -0.78 and a beta of 0.74. The firm’s 50 day simple moving average is $4.66 and its two-hundred day simple moving average is $6.14.
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.31. The firm had revenue of $69.81 million during the quarter, compared to analysts’ expectations of $69.20 million. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%. Research analysts expect that Vanda Pharmaceuticals Inc. will post -2.53 EPS for the current fiscal year.
Key Headlines Impacting Vanda Pharmaceuticals
Here are the key news stories impacting Vanda Pharmaceuticals this week:
- Positive Sentiment: Director Charles Cliff Duncan bought a combined 10,000 shares from November 3–5 for approximately $38,069, increasing his ownership. SEC ownership filing
- Neutral Sentiment: HC Wainwright maintained its Buy rating and raised its 2026 EPS estimate to a loss of $2.45 from a loss of $3.03, including a narrower projected Q4 loss.
- Negative Sentiment: HC Wainwright lowered estimates for Q2–Q4 2027 and cut its full-year 2027 EPS forecast to a loss of $1.02 from a loss of $0.94, signaling a less favorable outlook for those periods.
Hedge Funds Weigh In On Vanda Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Vanda Pharmaceuticals in the second quarter worth about $46,841,000. AIGH Capital Management LLC purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at approximately $12,510,000. State Street Corp grew its holdings in Vanda Pharmaceuticals by 16.6% during the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock valued at $21,520,000 after buying an additional 500,843 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Vanda Pharmaceuticals by 11.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock valued at $25,979,000 after buying an additional 378,598 shares in the last quarter. Finally, Ieq Capital LLC bought a new stake in Vanda Pharmaceuticals in the 2nd quarter worth approximately $1,731,000. Institutional investors own 88.14% of the company’s stock.
Analyst Ratings Changes
VNDA has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday. Oppenheimer started coverage on Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Wall Street Zen upgraded Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 31st. Finally, B. Riley Financial reissued a “buy” rating and set a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $13.50.
Check Out Our Latest Stock Analysis on VNDA
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.
Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.
Read More
- Five stocks we like better than Vanda Pharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
